JianleWang Ph.D.

Associate

サンディエゴ + 1.858.314.1167

Connect:

共有

Dr. Jianle Wang represents pharmaceutical and biotech companies on the procurement and protection of intellectual property. Jianle's practice encompasses global patent portfolio development and management, due diligence investigation, patentability and validity assessments, freedom-to-operate analysis, and patent strategy counseling.

Jianle has experience with a wide range of technologies, including immunotherapies (e.g., antibodies, antibody-drug conjugates, cell-based therapies, CAR-T cell technology), biomarkers and diagnostics, small-molecule pharmaceuticals, cancer treatment, stem cells, and therapeutic polypeptides.

Jianle has worked on representative matters for Merck, AbbVie, and NGM Biopharmaceuticals.

Prior to joining Jones Day, Jianle worked as a scientist for more than 10 years and performed her postdoctoral research at the University of Pennsylvania.

Jianle is actively involved in the Firm's pro bono practice that includes representing individuals seeking asylum in the United States.

担当案件

  • Epic Sciences builds patent portfolio for clinical applications of single cell diagnosticsJones Day assists Epic Sciences, Inc. with counseling and development of global patent portfolios related to clinical applications of methods for analyzing and categorizing rare circulating cells, such as diagnosing cancers, analyzing heterogeneity of disease, and predicting resistance to therapies.
  • Epic Sciences develops global patent portfolio for diagnostics involving rare circulating cellsJones Day is assisting Epic Sciences, Inc. with counseling and development of global patent portfolios related to methods for analyzing and categorizing rare circulating cells, e.g., circulating tumor cells (CTCs), circulating endothelial cells (CECs).
  • VST Bio establishes global patent portfolios related to anti-syndecan-2 antibodies for the treatment of diseases related to vascular permeabilityJones Day is representing VST Bio Corp. in connection with the establishment of a global patent portfolio related to antibodies that target syndecan-2 and uses thereof in the treatment of diseases related to vascular permeability and leakage, including ischemic stroke and myocardial infarction.
    •

    April 2024 Commentary

    FTC Weighs In on Orange Book Listing of Drug-Device Patents

    送信する前の注意事項：

    www.jonesday.comに掲載されている情報は、一般的な使用を目的としており、法的アドバイスを目的としたものではありません。このEmailを送信することにより、弁護士を含む専門家・依頼者の関係を構築することを意図するものではなく、このEmailの受領はそのような関係を構築するものではありません。当事務所に送信されたいかなる情報も、業務委託契約を結ばない限り、弁護士等が依頼者に対して守秘義務を負う機密事項として取り扱われることはありません。このEmailの送信者は以上の注意事項の内容を読み、理解したものと判断します。